Medically reviewed by Dr. Petch
Dr. Petch β International Board of Lifestyle Medicine (IBLM) β Diplomate
Last reviewed: July 11, 2026
Yes β stem cell therapy is legal in Thailand, but it is regulated rather than unrestricted. Oversight is shared by three authorities: the Thai FDA, the Medical Council of Thailand, and the Ministry of Public Health. Thai law separates minimal-manipulation procedures from Advanced Therapy Medicinal Products (ATMP), which face stricter manufacturing and registration rules. Any therapy must be delivered by a licensed physician in a licensed facility, after a documented medical assessment and informed consent.
Key Takeaways
- Cell therapy is legal but regulated in Thailand β overseen jointly by the Thai FDA, the Medical Council of Thailand, and the Ministry of Public Health.
- Thai regulation classifies products involving more than minimal manipulation as Advanced Therapy Medicinal Products (ATMP).
- ATMPs require PIC/S-standard GMP manufacturing and Thai FDA product registration; minimal-manipulation procedures fall under Good Tissue Practice.
- MSC, CAR-T, NK, dendritic, and iPS cell products typically fall in the ATMP category because they are more than minimally manipulated.
- Every therapy requires a licensed physician, a licensed facility, a documented medical assessment, informed consent, and adverse-event reporting.
Who Regulates Cell Therapy in Thailand
Oversight of cell and stem cell therapy in Thailand is shared across three bodies, each with a distinct remit. Understanding the split explains why a compliant provider answers to more than one authority.
- Thai FDA β regulates cell-based products themselves, including manufacturing standards and, for Advanced Therapy Medicinal Products, product registration.
- Medical Council of Thailand β governs physician conduct and the ethics of clinical practice, including what may be offered and how it is described to patients.
- Ministry of Public Health β licenses the medical establishments in which therapies are delivered.
The Medical Council's ethical regulation requires that clinical uses be evidence-based or conducted within ethics-committee-approved research. Presenting experimental therapy as proven is prohibited, and guarantees of outcome are not permitted. Together, these three authorities set the boundaries within which any legitimate cell therapy operates.
The ATMP Framework: Minimal Manipulation vs ATMP
The pivotal distinction in Thai regulation is how much a cell product is processed before use. Thai regulation formalizes the line between minimally manipulated tissue and products that are more than minimally manipulated β the latter classed as Advanced Therapy Medicinal Products (ATMP). The category determines which standard applies.
| Category | Definition | Examples | What the law requires |
|---|---|---|---|
| Minimal manipulation | Cells or tissue kept close to their natural state, without culture, expansion, genetic modification, or activation. | Hematopoietic (blood) cell transplantation, platelet-rich plasma (PRP), amniotic membrane. | Good Tissue Practice standards; delivery by a licensed physician in a licensed facility. |
| ATMP (more than minimal manipulation) | Products altered through cell culture, expansion, genetic modification, or activation. | Mesenchymal stem cells (MSCs), CAR-T, NK cells, dendritic cells, iPS-derived products. | PIC/S-standard GMP manufacturing plus Thai FDA product registration, in addition to physician and facility licensing. |
The distinction is not a ranking of safety or value β it reflects how much a product has been processed and therefore how it is regulated. Because MSCs are typically expanded in culture, they generally sit in the ATMP category. Confirming the category of a specific protocol, and the standard it follows, is a question for the treating physician.
What This Means for Patients
The framework gives anyone considering cell therapy a practical checklist. These questions apply to any clinic, anywhere in Thailand β use them to confirm a provider is operating inside the rules rather than around them.
- Licensed physician β care is directed by a physician licensed to practice in Thailand, not delegated to non-medical staff.
- Licensed facility β the therapy is delivered in an establishment licensed by the Ministry of Public Health.
- Assessment first β a documented medical assessment precedes any protocol; nothing is prescribed on request alone.
- Informed consent β benefits, risks, and limits are explained clearly, in writing, before you proceed.
- Sourcing and standard β the provider can explain how the cell product is manufactured and whether it follows Good Tissue Practice or GMP.
- No guarantees β be cautious of guaranteed results or experimental therapy described as proven; both are prohibited under the Medical Council's rules.
If a provider cannot answer these plainly, that is itself an answer. Regulation exists to protect patients, and a compliant house treats these questions as routine.
How a Doctor-Led House Approaches This
At Healthi Life, every protocol begins with a physician assessment and consultation; eligibility and the appropriate pathway are determined case by case with the physician. Cell-based options sit within our Recovery & Performance medicine, where the first step is always evaluation β never a protocol on request.
For guests exploring their options, the starting point is a conversation, not a treatment. You can read more about our physician-led stem cell therapy programs, or bring your questions directly to a consultation, where the appropriate pathway is discussed against your own health and goals.
Physician-Led Regenerative Medicine at Healthi Life
Our stem cell therapy programs sit within Recovery & Performance medicine at Bangkok's longevity house β every pathway defined with a physician.
All programs begin with physician assessment. No protocol is prescribed without context. Precision interventions. Long-term strategies. No shortcuts.
References
This page is educational and does not constitute medical or legal advice. Regulatory details can change β confirm the current position with a licensed physician or the relevant authority.
- Thai Food and Drug Administration (Thai FDA) β en.fda.moph.go.th (regulation of cell-based products and ATMP registration).
- Medical Council of Thailand β tmc.or.th (physician conduct and ethical regulation of clinical practice).
- The Nation Thailand β reporting on the regulatory update reclassifying advanced cell therapy products in Thailand: nationthailand.com.

Dr. Sarassawadee Suwanjinda (Dr. Petch)
Verified PhysicianCo-Founder & Chief Medical Strategy Officer
International Board of Lifestyle Medicine (IBLM) Diplomate
Dr. Sarassawadee Suwanjinda (Dr. Petch) is Co-Founder & Chief Medical Strategy Officer at Healthi Life, an International Board of Lifestyle Medicine (IBLM) Diplomate. She leads the longevity programs β biological-age and biomarker-driven protocols designed and re-tested over time.

